Stay updated on High Dose Cytarabine + Pembrolizumab in AML Clinical Trial

Sign up to get notified when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The study record for a Phase 2 trial of high-dose cytarabine followed by pembrolizumab in relapsed or refractory AML is displayed, including its design, eligibility criteria, outcome measures, locations, and study documents.
    Difference
    47%
    Check dated 2026-11-11T01:31:06.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T23:42:57.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice about the terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page. The displayed site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:45:10.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.7.1 instead of v3.7.0. The page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-07T00:15:14.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previously visible study details and related content. The study record information is no longer accessible on the page.
    Difference
    18%
    Check dated 2026-09-23T01:06:21.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now displays revision v3.7.0, replacing the previous v3.6.6. This indicates the study page has been updated to a newer version.
    Difference
    0.1%
    Check dated 2026-09-16T00:16:10.000Z thumbnail image

Stay in the know with updates to High Dose Cytarabine + Pembrolizumab in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the High Dose Cytarabine + Pembrolizumab in AML Clinical Trial page.